Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Status:
Terminated
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 1/Phase 2 study is to evaluate how the body handles the drug and
the drug's effect on the body of participants with mild cognitive impairment (MCI) due to
Alzheimer's Disease (AD) or mild AD and who test positive for amyloid plaque.